215 related articles for article (PubMed ID: 36985529)
1. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
Lai X; Yao F; An Y; Li X; Yang XD
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
[TBL] [Abstract][Full Text] [Related]
2. Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine.
Yao F; An Y; Lai X; Li X; Yu Z; Yang XD
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7515-7527. PubMed ID: 36966395
[TBL] [Abstract][Full Text] [Related]
3. Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.
An Y; Li X; Yao F; Duan J; Yang XD
Molecules; 2022 Feb; 27(5):. PubMed ID: 35268583
[TBL] [Abstract][Full Text] [Related]
4. A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.
Liu D; Wang J; You W; Ma F; Sun Q; She J; He W; Yang G
Front Immunol; 2023; 14():1228581. PubMed ID: 37529049
[TBL] [Abstract][Full Text] [Related]
5. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
6. Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade.
Wei Y; Qin G; Wang Z; Zhao C; Ren J; Qu X
ACS Nano; 2023 Mar; 17(6):5808-5820. PubMed ID: 36916491
[TBL] [Abstract][Full Text] [Related]
7. Light-controlled elimination of PD-L1+ cells.
Wong JJW; Selbo PK
J Photochem Photobiol B; 2021 Dec; 225():112355. PubMed ID: 34768077
[TBL] [Abstract][Full Text] [Related]
8. Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo.
Li T; Yao F; An Y; Li X; Duan J; Yang XD
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670583
[TBL] [Abstract][Full Text] [Related]
9. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety.
Zhang J; Li W; Qi Y; Wang G; Li L; Jin Z; Tian J; Du Y
Angew Chem Int Ed Engl; 2023 Jan; 62(5):e202214750. PubMed ID: 36458940
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
13. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Lee CK; Atibalentja DF; Yao LE; Park J; Kuruvilla S; Felsher DW
Nanotheranostics; 2022; 6(3):243-255. PubMed ID: 35145835
[No Abstract] [Full Text] [Related]
14. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
15. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.
Pham LM; Poudel K; Ou W; Phung CD; Nguyen HT; Nguyen BL; Karmacharya P; Pandit M; Chang JH; Jeong JH; Ku SK; Yong CS; Choi HG; Kim JO
Int J Pharm; 2021 Aug; 605():120816. PubMed ID: 34161810
[TBL] [Abstract][Full Text] [Related]
18. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.
Yu Y; Li J; Song B; Ma Z; Zhang Y; Sun H; Wei X; Bai Y; Lu X; Zhang P; Zhang X
Biomaterials; 2022 Jan; 280():121312. PubMed ID: 34896861
[TBL] [Abstract][Full Text] [Related]
19. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
Sun Z; Zhang Y; Cao D; Wang X; Yan X; Li H; Huang L; Qu X; Kong C; Qin H; Wang M; Xu W; Liang L
Drug Deliv; 2018 Nov; 25(1):1746-1755. PubMed ID: 30394118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
